Sign inJoin waitlistJoin the waitlist

Ranjit Nair

Assistant Professor · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2017–2018
Hematology and Medical Oncology
Lehigh Valley Health Network
2014–2017
Internal Medicine
Lehigh Valley Health Network
2011–2014
Doctor of Medicine
2005–2009
2002-2008 Medical School
2002–2008

Research

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Nature Medicine · 2023 · 216 citations
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Blood Advances · 2020 · 198 citations
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Blood · 2021 · 193 citations

Sattva Neelapu
49 papers
Jason Westin
47 papers
Paolo Strati
47 papers
Sairah Ahmed
46 papers
Loretta Nastoupil
44 papers
Christopher Flowers
41 papers
RS
Raphael Steiner
39 papers · 23 as a fellow
Swaminathan Iyer
37 papers
Luis Fayad
34 papers
Hun Lee
28 papers · 2 as a resident
Chelsea Pinnix
27 papers
Jillian Gunther
22 papers

Clinical trials

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2027
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2024–2027
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2015–2026